focus -WSS

focus

author：entertainment 2025-08-19 18:03:36 - browse：16327

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Medicare drug price negotiation program allowed for now

WSS

Would Medicare drug price negotiations stall in a shutdown?

Mindstrong's demise and the future of mental health care

FDA warns medical device makers about rise in fabricated data

Cigna to pay $172 million to settle Medicare Advantage fraud probe

WATCH: Why do our ears pop?

Listen: Who gets the credit for GLP

explore

focus

focus

Medical records are filled with copy

Measles policy set amid Florida outbreak alarms vaccine proponents

Drug repurposing or repositioning? The language matters

Researchers tackle phage therapy hurdles for wider adoption

New air purifier tech could be key to improving indoor air quality

Health tech startups drop sharply from 2021 highs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

What does generative AI mean for health care? We asked experts

Covid vaccines: Private market messier than government rollout

entertainment

Researchers tackle phage therapy hurdles for wider adoption

Measles policy set amid Florida outbreak alarms vaccine proponents

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Intercept Pharmaceuticals sells itself for less than $1 billion

Address the ethical violations that led to 'Three Identical Strangers'

leisure time

hotspot

hotspot

knowledge